$GDTC News

CytoMed Therapeutics Refutes Recent Statements Regarding Inaccurate, Misleading Claims About Company's Research Programs, Clinical Progress, And Operations

CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital

CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia

CytoMed Therapeutics Enters MoU With Universiti Malaya Medical Centre To Establish Phase 1 Clinical Trial Site To Investigate Safety And Efficacy Of CTM-GDT for No-Option Cancer Patients

CytoMed Therapeutics Enters MoU With Universiti Malaya Medical Centre To Establish Phase 1 Clinical Trial Site To Investigate Safety And Efficacy Of CTM-GDT for No-Option Cancer Patients

CytoMed Therapeutics Enters Into MOU With UMMC To Establish Phase I Clinical Trial To Investigate Safety And Efficacy Of CytoMed's Patented Allogeneic Unmodified Gamma Delta T Cells For No-Option Cancer Patients In Malaysia

CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy

CytoMed Therapeutics' LongevityBank Secures A Non-Dilutive Investment From ICH Capital Of Up To $500K

CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95%

CytoMed Therapeutics Chairman Increases Effective Holdings To 21.95% Through Open Market Purchases Of 105,824 Shares

CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets

CytoMed Therapeutics Submits Cash Bid To Acquire TC BioPharm; Terms Not Disclosed

CytoMed Therapeutics Limited (GDTC) Q2 2025 Earnings Call Prepared Remarks Transcript

CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia

Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition

CytoMed Expands Clinical-Scale NK Cells From Decade-Old Cord Blood; Forms New Cord Blood-Derived Biotech Under LongevityBank To Drive Growth And Revenue

Reported Earlier, CytoMed Therapeutics Limited Announces At The Market Offering Program For Up To $4.3M In Ordinary Shares Through R.F. Lafferty & Co Inc

CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program

Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies

CytoMed Therapeutics Completes Dose Level 1 For Its First-In-Human Phase I Dose-Escalation Clinical Trial (NCT05302037) For Four Late Stage Cancer Patients And Is Scheduled To Start Dose Level 2 Of The Angelica Trial In Q3 2025